Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revised EU Guide Addresses Ambiguities In Reporting of Safety Info From Trials

Executive Summary

The pharmaceutical industry is hoping that changes to the EU guideline on the management and presentation of reference safety information (RSI) in clinical trial applications will help companies struggling with new regulatory focus on this complex subject.

You may also be interested in...



Un-blinding, Pharmacovigilance Issues Among Top GCP Findings, Says UK Inspector

A UK good clinical practice inspector discusses common findings issued in relation to clinical trials as well as the challenges posed by new technologies, such as use of apps on smartphones and electronic patient diaries to record outcomes.

EU Guide To Tackle Inconsistent Reporting Of Reference Safety Info In Trials

An EU guideline on the complex subject of how drug sponsors should present and manage the reference safety information in their clinical trial applications is nearing finalization. For the past several months, drug companies have been grappling with an increased regulatory focus on RSI, which has resulted in their trial applications being rejected or studies being significantly delayed.

Solving The Trial Safety Information Puzzle: Regulators And Industry Pitch In

The UK regulatory agency, the MHRA, has identified a range of problems in the way that companies manage clinical trial reference safety information, although views as to what needs to be done to address these issues differ between the regulators and the regulated.

Related Content

Topics

UsernamePublicRestriction

Register

PS122174

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel